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Abstract
Aims. Prevalence of the use of antipsychotics (APs) in the paediatric population is globally
increasing. The aim of this study was to describe multinational trends and patterns in AP
use in children and adolescents in Europe.
Methods. This was a dynamic retrospective cohort study comprising all children and adolescents
(⩽18 years of age). Data were extracted from five population-based electronic healthcare data-
bases in Europe (Denmark, Germany, Italy, the Netherlands and United Kingdom) from 2000
to 2010. Yearly prevalence and incidence of AP use was expressed per 1000 person-years (PYs).
Results. Prevalence increased from 1.44 to 3.41/1000 PYs (2008) in Denmark and from 2.07
to 4.35/1000 PYs in the NL (2009), moderately increased from 2.8 to 3.24/1000 in UK (2009)
and from 1.53 to 1.74/1000 PYs in Germany (2008) and remained low from 0.61 to 0.34/1000
PYs in Italy (2010). Similarly, incidence rates increased from 0.69 to 1.52/1000 PYs in
Denmark and from 0.86 to 1.49/1000 PYs in the NL, stabilised from 2.29 to 2.37/1000 PYs
in the UK and from 0.79 to 0.80/1000 PYs in Germany and remained low from 0.32 to
0.2/1000 PYs in Italy. AP use was highest in 15–18 year olds and in boys compared to
girls. Yet, the use observed in the 5–9 year olds was found to be comparatively high in the
NL. Prescriptions of second generation APs, especially risperidone, were privileged but the
first generation APs were still prescribed in the youngest.
Conclusions. A steady increase in AP use in children and adolescents was observed essentially
in the NL and Denmark. The use in Germany and Italy was lowest among countries. The use
of APs under 9 years of age underlines their off-label use and should be carefully monitored as
the risk/benefit ratio of these medications remains unclear in young children. AP use was
altogether lower in Europe as compared to that reported in North America.
Introduction
Antipsychotic (AP) medications are effective in treating several psychiatric conditions in chil-
dren and adolescents. Although not curative, they allow adequate control of clinical symptoms
in lifelong psychiatric diseases (Caccia et al., 2011). Yet, the use of APs is associated with a
substantial number of adverse effects in this population and different agents present highly
variable safety profiles (Pringsheim et al., 2011; Seida et al., 2012). Therefore, prescribing of
APs involves a difficult balance between the need to relieve mental disease symptoms and
the risk of drug-induced toxicity.
Over the past three decades, studies have consistently demonstrated that the prevalence of
the use of APs and duration of the AP therapy is increasing over time in the pediatric popu-
lation (Vitiello et al., 2009; Steinhausen and Bisgaard, 2014; Halfdanarson et al., 2017). Despite
marketing authorisations for the use of some first-and second-generation antipsychotics
(FGAs and SGAs) specifically in children and adolescents (Kaguelidou and Acquaviva,
2016), the vast majority of these medications are still prescribed ‘off-label’ in the pediatric
population. The observed increase in the use of APs probably reflects the ‘off-label’ prescribing
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of APs in non-psychotic disorders, such as attention deficit
hyperactivity disorder (ADHD) or disruptive behaviour, and in
children younger than the approved age ranges (Penfold et al.,
2013).
However, the majority of these drug utilisation studies are
based on data from Northern American countries and informa-
tion on population-based use of these medications in Europe is
more limited (Zoega et al., 2009; Verdoux et al., 2010; Penfold
et al., 2013; Steinhausen and Bisgaard, 2014; Verdoux et al.,
2015; Waszak et al., 2018). Differences in the diagnosis and
management of psychiatric conditions as well as in the attitude
to prescribe APs may hinder extrapolation of results from one
continent to the other. In fact, with regard to the use of SGAs,
a wide inter-country variability was observed in a study from
the year 2000, where dispensations of SGAs represented 66% of
total AP use in children and adolescents in the US v. 48% in
the Netherlands and only 5% in Germany (Zito et al., 2008).
Therefore, the aim of this study was to describe the prevalence




Datawere extracted from five population-based electronic healthcare
databases in Europe. TheHealth Improvement Network (THIN) is a
database of primary care medical records of about 5.9 million
patients from 500 general practices (GPs) in the United Kingdom
(UK). The PHARMO Database Network is a patient-centric data
tracking system that captures medical information, including infor-
mation on drug dispensing, for approximately 4 million inhabitants
in 65 municipal areas in the Netherlands (NL). The Aarhus
University Hospital Database comprises medical information
including hospital and outpatient visits from 1.8 million inhabitants
inDenmark (DN). TheGerman Pharmacoepidemiological Research
Database (GePaRD) consists of claims data from four German statu-
tory health insurance providers, three of which accepted to contrib-
ute data for this study resulting in a source population of 8 million
insurants. Finally, the Emilia Romagna Regional database (ERD) is
a claims database that contains information on all reimbursable
healthcare services, including drugs, for about 4.5 million inhabi-
tants of the Emilia Romagna region in Northern Italy (IT). These
databases contain information from the healthcare records of almost
27 million European citizens. THIN contain records fromGP, while
PHARMO, AARHUS, GePARD and ERD are comprehensive
administrative/record-linkage systems in which drug dispensing
data for a well-defined population are linked to a registry of hospital
discharge diagnoses and various other registries.
All databases and their content have been extensively described
in previous ARITMO publications and have already been used for
the conduct of pharmacoepidemiological studies in compliance
with European guidelines for the use of medical data for research
(Holstiege et al., 2015; Mor et al., 2015; Oteri et al., 2016). Also,
methodological aspects of multiple database studies carried out
in ARITMO and other EU funded projects have been fully
described in a previous publication (Trifiro et al., 2014). Data
were analysed using a distributed network approach, in which
data holders maintain control over their original data and only
anonymised and aggregated data are shared. This was done through
the preparation of data according to a common data input model
followed by local data aggregation using custom-built software,
Jerboa© (Trifiro et al., 2014). The respective scientific and ethics
committees of each database approved the conduct of the study.
With regard to GePaRD, the use of data was approved by the statu-
tory health insurance providers and their authorities.
Study design and population
This was a dynamic retrospective cohort study. The study popula-
tion comprised all children and adolescents (⩽18 years of age),
registered with the databases during the study period with at least
1 year of valid data (except for newborns). The period for data col-
lection differed between databases. It was longer in NL and UK
(2000–2009) followed by DN (2001–2008), Germany (2005–
2008) and IT (2006–2010). Children were followed from the start
of the study period or, if later, the start of entry into the database
until their 19th birthday, the end of the study period, exit from
the database, death or latest data recorded, whichever came first.
Antipsychotic medications
All drugs under the ‘N05A’ pharmacological subgroup of the
Anatomic Therapeutic Chemical classification system (except for
lithium [N05AN]) were included. APs were sub-classified into
second-generation (clozapine, olanzapine, quetiapine, asenapine,
sulpiride, amisulpride, risperidone, aripiprazole, paliperidone, ilo-
peridone, ziprasidone and sertindole) and first-generation agents
(all the remaining). AP exposure was assessed using dispensing
and/or prescription data from all databases.
Statistical analysis
Prevalence of AP use was defined as the number of children and
adolescents that received at least one AP drug dispensing divided
by the number of person-years (PYs) of follow-up in the study per-
iod and expressed as rate per 1000 PYs. Incidence of AP use was
defined as the number of ‘new antipsychotic users’ per 1000 PYs.
‘New users’ were children and adolescents that had a first prescrib-
ing or dispensing of any AP drug after a drug-naïve period of 1 year.
Because of the dynamic nature of the population we used PYs
rather than the total number of individuals as denominators. Of
note, PYs of exposure of prevalent users were not included in the
denominator for calculation of the incidence of use. Both preva-
lence and incidence of use were estimated per calendar year and
stratified by sex, age group (⩽4, 5–9, 10–14 and 15–17 years) and
country. Prevalence and incidence estimates are provided with
95% confidence intervals (95% CI) calculated according to the
asymptotic method based on a normal approximation. Relative
changes (RC) in prevalence and incidence rates over the study per-
iod were expressed as percentage changes and calculated for each
country as the difference in prevalence or incidence between the
respective first and last year for which data was available, divided
by the prevalence or incidence in the first data year.
Dispensing frequency by class of AP agents (FGAs and SGAs),
age group and country was also measured. The number and type
of APs covering 90% of all AP dispensing (DU 90%) were esti-
mated by age group and country.
Data were described in narrative and tabular forms. Statistical
analyses were performed using the SAS software version 9.3 soft-
ware (SAS Inc, Cary, North Carolina).
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Results
During the study period, average annual study population and
population exposed to APs were respectively: 336.576 and 752
children and adolescents in DN, 1.340.163 and 1.949 in
Germany (GE), 768.631 and 2.206 in UK, 798.431 and 2.149 in
NL and 760.866 and 342 in IT.
Prevalence and incidence of AP use per country and calendar
year with 95% CI are shown in Figs 1 and 2, respectively.
Increases over time in prevalence and incidence rates were
observed in DN and NL. In DN, prevalence increased from 1.44
(CI 95%: 1.31–1.58; 2001) to 3.41/1000 PYs (CI 95%: 3.21–3.62;
2008) (+137% RC) and in NL, from 2.07 (CI 95%: 1.96–2.18;
2000) to 4.35/1000 PY (CI 95%: 4.19–4.52; 2009) (+110% RC).
Fig. 1. Prevalence of AP use by country and calendar year. PHARMO-NL: PHARMO Database Network, the Netherlands. THIN-UK: The Health Improvement Network,
United Kingdom. Aarhus-DN: Aarhus University Hospital Database, Denmark. GEP-GE: German Pharmacoepidemiological Research Database (GePaRD), Germany.
ERD-IT: Emilia Romagna Regional database, Italy.
Fig. 2. Incidence of AP use by country and calendar year. PHARMO-NL: PHARMO Database Network, the Netherlands. THIN-UK: The Health Improvement Network,
United Kingdom. Aarhus-DN: Aarhus University Hospital Database, Denmark. GEP-GE: German Pharmacoepidemiological Research Database (GePaRD), Germany.
ERD-IT: Emilia Romagna Regional database, Italy.
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Incidence rates increased from 0.69 (CI 95%: 0.6–0.79; 2001) to
1.52/1000 PY (CI 95%: 1.39–1.66; 2008) (+137% RC) in DN
and from 0.86 (0.79–1.93; 2000) to 1.49/1000 PYs (1.39–1.58;
2009) in NL (+73% RC).
In UK and Germany, no increase in the use of APs was seen.
In UK, prevalence and incidence changed respectively, from 2.8
(CI 95%: 2.67–2.93; 2000) to 3.24/1000 PYs (CI 95%: 3.1–3.38;
2009) (+16% RC) and from 2.29 (CI 95%: 2.18–2.41; 2000) to
2.37/1000 PYs (CI 95%: 2.25–2.49; 2009) (+3.5% RC). Of note,
the UK had the highest incidence rates observed among all coun-
tries. In Germany, prevalence changed from 1.53 (CI 95%: 1.46–
1.6; 2005) to 1.74/1000 PYs (CI 95%: 1.67–1.82; 2008) (+14% RC)
and incidence remained stable from 0.79 (CI 95%: 0.74–0.84;
2005) to 0.8/1000 PYs (CI 95%: 0.75–0.85; 2008) (+1.2% RC).
The only country where both prevalence and incidence of AP
use slightly decreased over the years was IT. Prevalence amounted
to 0.61 (CI 95%: 0.55–0.68) in 2006 and 0.34/1000 PYs (CI 95%:
0.3–0.38) in 2010 (−44% RC) and incidence was 0.32 (CI 95%:
0.28–0.37) in 2006 and 0.2/1000 PYs (CI 95%: 0.17–0.23) in
2010 (−37.5% RC).
During the entire study period, the overall use (both preva-
lence and incidence) of APs was higher with increasing age,
with a maximal use observed between 15 and 18 years of age,
and more prevalent in boys than girls at all ages (Fig. 3).
However, maximal prevalence and incidence of use was observed
in boys between 10 and 14 years of age in NL and in girls between
15 and 18 years in the UK. Moreover, the use of APs in children
⩽4 years of age was null in Denmark, limited in IT and the high-
est in NL followed by UK and Germany.
The frequency of AP dispensing by type of AP, age group and
country for the year 2008 are illustrated in Fig. 4. Overall, SGAs
were more frequently prescribed than FGAs and this is most obvi-
ous in the latest data years in all countries (Table 1). Yet, wide
variation across different age groups was noted. In the youngest
(⩽4 years), FGAs were clearly preferred with the exception of
DN (22% of all prescriptions in 2008). The use of FGA decreased
with age and years of study accounting for less than 50% of pre-
scriptions in children above 4 years of age in all countries except
IT in the most recent data-available year. In IT, FGAs remain fre-
quently prescribed, 89% of all prescriptions in 5–9 years, 86% in
10–14 years and 78% in the 15–18 years age group. Of note, in the
UK, FGA still accounted for 44% of all AP prescriptions in ado-
lescents between 15 and 18 years of age, a percentage much higher
than those observed in the other countries with the exception of
IT. Variability in the use of FGA and SGA between countries and
age groups is shown in Fig. 4 for the calendar year 2008 which
was the only year with data available from all databases.
Ninety percent of all AP prescriptions (DU90%) in the popu-
lation were covered by 9 drugs in IT, 8 in Germany, 6 in DN, 4 in
NL and 5 in UK. Although, the number of drugs accounting for
the DU90% increased with age, it is noteworthy that in the 0–4
years age group the number of prescribed drugs was higher
than that in the 5–9 years group (Table 2). Risperidone is the
most frequently prescribed AP in all countries with the exception
of IT where chlorpromazine is generally prescribed at all ages.
Also, prochlorperazine, an AP with mainly antiemetic properties,
was the most commonly prescribed drug in the UK at all ages also
prescribed in the NL in the ⩽4 years age group.
Discussion
This study provides a comprehensive overview of the use of APs
in children and adolescents in five European countries: Denmark,
Germany, Italy, the Netherlands and the United Kingdom.
Prevalence and incidence of use varied widely between countries.
The use was globally more important among adolescents however,
that observed in younger age groups (5–9 years) was found to be
comparatively high in the Netherlands. Prescriptions of SGAs
were privileged over the years except for the youngest age groups
where clinicians still favoured FGAs with the exception of one
country.
Fig. 3. Prevalence and incidence rates per sex, age group and country. NL: the Netherlands; UK: United Kingdom; DN: Denmark; GE: Germany; IT: Italy; F: female
users; M: male users.
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In the recent years, several studies have alerted on the increas-
ing rate of AP use worldwide in children and adolescents
(Halfdanarson et al., 2017; Kalverdijk et al., 2017) yet, there are
few published AP utilisation studies in Europe. The present
study showed that the point prevalence of AP use almost doubled
over the years in countries like the NL and DN; however, the
increase was moderate in the UK and Germany and the preva-
lence rate actually decreased in IT. These results are in accordance
with some previously published studies. In the NL, estimations of
prevalence in a previous study ranged from 3‰ in 1997 to 6.8‰
in 2005 (Kalverdijk et al., 2008). Accordingly, in DN where the
prevalence of use was very low in 1996 (0.3‰), it increased
over 6-fold in 2010 (Steinhausen and Bisgaard, 2014). For these
two countries, increasing rates were also reflected in the incidence
rates and were confirmed in more recent international utilisation
studies that covered larger study periods and different databases
(Halfdanarson et al., 2017; Kalverdijk et al., 2017). It is highly
probable that this is related to frequent ‘off-label’ prescription
of APs, particularly in the youngest, mainly to treat ADHD, con-
duct and behavioural disturbances (aggression, self-injury, disrup-
tive behaviour, etc.) and mood disorders without solid efficacy
and safety evidence for this practice (Penfold et al., 2013;
Baribeau and Anagnostou, 2014; Hawton et al., 2015; Loy et al.,
2017). Nevertheless, increasing public awareness of pedopsychia-
tric disorders, greater acceptance of the use of psychotropic med-
ications in children and a subsequently increasing demand for
quickly effective therapies in these countries may stimulate AP
prescribing. National pedopsychiatry therapeutic guidelines can
also explain such practices and inter-country differences though
most of the guidelines in Europe plead for non-pharmacological
therapeutic approaches especially in AP ‘off-label’ indications
such as ADHD or neurotic disorders (Taylor et al., 2004;
Hodgkins et al., 2013). Regulatory approvals for APs are also har-
monised across Europe and thus less susceptible to explain inter-
Fig. 4. Frequency of dispensing of AP drugs by type of AP, age group and country for year 2008. FGA: first generation antipsychotics, SGA: second generation anti-
psychotics. NL: the Netherlands; UK: United Kingdom; DN: Denmark; GE: Germany; IT: Italy
Table 1. Percentage of FGA prescriptions on total AP prescriptions in the first









0–4 years IT 84 100 IT: 2006–2010
GE 93 66 GE: 2005–2008
DN 100 22 DN: 2001–2008
NL 83 63 NL: 2000–2009
UK 99 100 UK: 2000–2009
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Table 2. APs that cover 90% of all prescriptions per country and age group during available data years
IT Germany DN NL UK
Drug % Drug % Drug % Drug % Drug %
0–4 years
Chlopromazine 32.7 Pipamperone 28.3 Levomepromazine 39.1 Moperone 59.0 Prochlorperazine 85.3
Haloperidol 12.2 Promazine 28.1 Chlorprothixene 32.3 Risperidone 22.3 Risperidone 4.6
Pimozide 10.2 Risperidone 16.4 Risperidone 28.6 Haloperidol 8.2 Haloperidol 4.3
Levomepromazine 9.3 Levomepromazine 6.6 Prochlorperazine 2.5
Periciazine 9.3 Melperone 5.6
Clotiapine 8.3 Chlorprothixene 3.8
Amisulpride 5.4 Tiapride 3.6
Quetiapine 3.4
5–9 years
Chlopromazine 25.7 Risperidone 52.5 Risperidone 68.3 Risperidone 64.2 Risperidone 48.6
Haloperidol 18.0 Pipamperone 22.7 Pimozide 17.4 Pipamperone 26.3 Prochlorperazine 39.4







Chlopromazine 22.0 Risperidone 47.0 Risperidone 59.9 Risperidone 59.2 Risperidone 50.4
Haloperidol 14.1 Tiapride 21.3 Pimozide 15.2 Pipamperone 23.7 Prochlorperazine 32.8
Pimozide 13.5 Pipamperone 18.0 Chlorprothixene 10.4 Pimozide 5.0 Haloperidol 4.9
Periciazine 13.3 Olanzapine 1.8 Quetiapine 3.6 Olanzapine 3.0 Thioridazine 2.0
Levomepromazine 10.9 Chlorprothixene 1.8 Ziprasidone 3.6
Risperidone 10.1 Quetiapine 1.8
Clotiapine 6.9
15–18 years
Chlopromazine 22.6 Risperidone 32.0 Risperidone 39.9 Risperidone 46.3 Prochlorperazine 40.2
Haloperidol 14.1 Pipamperone 11.0 Chlorprothixene 14.3 Pipamperone 18.8 Risperidone 29.1
Clotiapine 14.0 Quetiapine 10.6 Olanzapine 13.9 Olanzapine 10.0 Olanzapine 9.8
Periciazine 9.9 Olanzapine 9.2 Quetiapine 9.2 Quetiapine 7.7 Quetiapine 4.3
Levomepromazine 8.2 Tiapride 7.5 Pimozide 4.4 Pimozide 5.2 Chlopromazine 3.4
Pimozide 7.6 Chlorprothixene 4.1 Aripiprazole 4.1 Haloperidol 4.7 Haloperidol 2.8
Risperidone 6.3 Clozapine 4.0 Levomepromazine 3.9 Sulpiride 1.8
Olanzapine 3.9 Melperone 3.7 Ziprasidone 3.6
Quetiapine 2.7 Aripiprazole 2.7
Amisulpiride 2.3 Levomepromazine 2.5
Sulpiride 2.4
Perazine 2.3
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country differences in use. Therefore, reasons for increasing AP
use in NL and DN should be specifically explored.
In the UK, prevalence of AP use doubled between 1992 and
2005 (0.39 to 0.77‰) (Rani et al., 2008) but our estimations,
although comparatively higher, showed that the increase between
2000 and 2009 was slight. Apart from the differences in study per-
iod and data sources used, another possible explanation for the
higher prevalence estimation in the present study is that it also
included the use of prochlorperazine, which is an AP frequently
prescribed in the UK as an antiemetic agent. The latter may
also explain why the number of new AP users was close to the
number of prevalent users in the country and that incidence of
use was the highest observed among all countries. In Germany,
recent studies described prevalence ranging from 2.03‰ in
2006 to 2.61‰ in 2011 (Schroder et al., 2017) and 3.3‰ in
2012 (Kalverdijk et al., 2017). Our prevalence estimations are
lower which is probably related to the difference in study
periods, study populations and/or methodological approaches.
Nonetheless, they described the same discreet increment in use
over the years. Both in the UK and in Germany, incidence rates
were unchanged during the study period. Hence, the slight
increases in prevalence observed were most probably due to an
increase in the duration of the AP treatment rather than an
increase in the number of prescriptions to newly diagnosed users.
Finally, a previous Italian study described a decrease in the
prevalence of AP use from 0.63‰ in 1998 to 0.53‰ in 2004
(Clavenna et al., 2007) and this tendency was confirmed in our
updated data. Globally, the increase in the use of APs observed
worldwide has been largely attributed to their off-label use in
pedopsychiatry. However, it is possible that in Italy other classes
of psychotropic drugs such as antidepressants may be more
largely prescribed especially in behaviour disorders or autism
(Clavenna et al., 2007; Clavenna et al., 2011; Piovani et al.,
2016). Also, the low prevalence of AP use and the very low pre-
scription rate of SGAs observed in the ERD might be explained
by the fact that, in Italy, these drugs are partially dispensed
through direct distribution from local psychiatric services and
cannot be captured in the outpatient pharmaceutical dispensing
flow. As a consequence, an underestimation of the use of APs
especially SGA may have occurred.
Altogether, European prevalence rates were lower than those
described in the US (39.4‰ per 2-year interval) (Cooper et al.,
2006) but in Canada, prevalence is comparable to that in the
NL (1.66 in 1996 to 6.37% in 2001) (Ronsley et al., 2013) although
data were not available on the same study period.
Another interesting finding was the age distribution of AP
prescriptions. Countries like NL have a very high use of APs in
the youngest age groups (0–4 years and 5–9 years) followed by
the UK, Germany and Denmark whereas in IT, use is very low
in children of less than 9 years of age. Onset of psychotic disor-
ders typically occurs in adolescence as opposed to conduct or aut-
istic disorders associated with aggressive behaviour that can be
detected in rather young ages. Therefore, high use in the youngest
underlines the off-label use of AP agents for the treatment of a
wide range of psychiatric illnesses without solid efficacy evidence
and despite major concerns regarding their safety profile espe-
cially in very young children (Fraguas et al., 2011; Ho et al.,
2011; Kaguelidou and Acquaviva, 2016; Pisano et al., 2016).
The extent of the off-label use highly varies between countries
and it would be useful to monitor this use by assessing the
ratio of prevalence rates as described in this study. On the other
hand, gender differences with a higher use in boys compared to
girls have been observed as expected in these pathologies
(Ronsley et al., 2013; Kalverdijk et al., 2017). The only exception
was in the UK where girls in the 15–18 years of age had the higher
prevalence and incidence of use mainly due to the prescription of
prochlorperazine.
The nature and the number of prescribed AP agents also var-
ied among countries and age groups. Altogether, there is a clear
tendency in limiting FGAs prescribing over the years.
Risperidone was the most frequently prescribed SGA in almost
all countries. This is highly consistent with numerous national
and international AP utilisation reports (Rani et al., 2008;
Ronsley et al., 2013; Halfdanarson et al., 2017). Switch in the
early 2000s was initially triggered by the fact that SGAs were mar-
keted as being overall safer than FGAs. Since then, SGAs have
indeed been associated with a lower risk of neurological adverse
reactions than FGAs but they have been clearly associated with
a higher risk of weight gain and metabolic abnormalities in
both adults and children (Maher et al., 2011; Seida et al., 2012;
Caccia, 2013). Also, despite initial expectations, variability in
APs’ safety profile appears to be greater among specific SGA
agents than between FGA and SGA classes (Fraguas et al., 2011;
Masi and Liboni, 2011; Kaguelidou and Acquaviva, 2016). Yet,
based on our findings, the switch from FGAs to SGAs concerned
essentially the older paediatric age groups. In the youngest groups,
FGAs were still commonly prescribed even in the most recent
study years underlining the fact that in paediatric medical prac-
tice, new molecules without specific marketing authorisation are
initially prescribed ‘off-label’ in adolescents and older children
until more knowledge becomes available on their efficacy and
safety. Certainly, inter-country differences observed in the choice
of prescribed molecules are directly related to differences in mar-
ket availability, variation in the diagnosis of paediatric psychiatric
disorders, prescribers’ habits and therapeutic approaches.
The results of the present study should be considered in view
of some limitations. Firstly, we used outpatient prescription/dis-
pensing data and had no information about the actual adherence
of patients to their treatment and therefore, the real use of these
medications. In addition, use in inpatient/institutionalised chil-
dren and adolescents has not been assessed although it is unlikely
that an AP therapy initiated in an hospital/institution would be
discontinued in the outpatient setting especially since recommen-
dations urge to minimise inpatient journeys in minors. Secondly,
we do not directly compare national utilisation data given the
differences in the nature of corresponding databases. Also, we
acknowledge quantitative differences with some more recent
studies published in the field. However, despite such differences,
conclusions remain the same; some European countries have an
already high and increasing rate of AP use (north of Europe)
where in others, including UK and Germany, the rates are less
important and increasing in a slower pace. In addition, we present
data from Italy, a country that had not been previously included
in multinational studies. Finally, we did not describe AP poly-
pharmacy or therapeutic associations with other psychotropic
drug classes as this was beyond the scope of the present study.
Conclusions
The use of APs varies widely among European countries, with
some presenting an increase in use over the years and others, a
stabilisation or slight decrease. While the use is overall higher
in adolescents, in some countries there is a clear increase of AP
prescribing in younger children. SGAs overall dominate
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prescribing preferences but FGAs are still prescribed in the young-
est in varying proportions. The use of APs in children of ⩽9 years
of age underlines their off-label use and should be carefully mon-
itored as the risk/benefit ratio of these medications remains
unclear especially in the youngest. Future studies should focus
on exploring factors that drive AP use in children and adolescents
in each country specifically. As the regulatory context regarding
APs is quite homogenous in Europe, it is possible that societal
and parental awareness and demands as well as prescribers’
preferences play a determining role.
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